Loading clinical trials...
Loading clinical trials...
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
Conditions
Interventions
75 mg linzagolix tablet
200 mg linzagolix tablet
+4 more
Locations
71
United States
Achieve Clinical Research/ ID # 601
Birmingham, Alabama, United States
Choice Research, LLC/ ID # 609
Dothan, Alabama, United States
Southeast Clinical Research/ ID # 618
Chiefland, Florida, United States
Universal Axon - Homestead, LLC/ ID # 620
Homestead, Florida, United States
Multi-Specialty Research Associates, Inc./ ID # 625
Lake City, Florida, United States
Wellington Anti-Aging, LLC/ ID # 613
Loxahatchee Groves, Florida, United States
Start Date
June 13, 2019
Primary Completion Date
October 18, 2021
Completion Date
April 1, 2022
Last Updated
April 2, 2025
NCT05951452
NCT06611501
NCT05726786
NCT07241637
NCT04567771
NCT07215130
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions